Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer

Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $30 but keeps an Outperform rating on the shares. Shares have rebounded as investors are getting more comfortable with the regulatory strategy for bexobrutideg, and specifically its odds for accelerated approval, the analyst tells investors in a research note. The company has been having ongoing discussions with the FDA as part of bexdeg’s Fast Track designation, and while management continues to state publicly that accelerated approval will be a review issue, there’s been some changes to the language in the company’s most recent corporate deck that suggests the FDA is onboard with the plan, the firm added.